Literature DB >> 24726310

Emphysematous pyelonephritis: multicenter clinical and therapeutic experience in Mexico.

Daniel Olvera-Posada1, Ghislaine Armengod-Fischer2, Luis G Vázquez-Lavista3, Miguel Maldonado-Ávila2, Emmanuel Rosas-Nava2, Hugo Manzanilla-García2, Ricardo A Castillejos-Molina1, Carlos E Méndez-Probst1, Mariano Sotomayor1, Guillermo Feria-Bernal1, Francisco Rodríguez-Covarrubias4.   

Abstract

OBJECTIVE: To analyze the outcomes of emphysematous pyelonephritis (EPN), the impact of different treatment modalities, and to determine risk factors associated with mortality.
METHODS: We retrospectively reviewed cases of EPN from 3 tertiary care institutions in Mexico. The diagnosis was confirmed with computed tomographic scan. Treatment was classified as follows: medical management (MM), minimally invasive, and surgical. Demographic, clinical, biochemical, and radiological characteristics were assessed and compared between survivors and nonsurvivors. Comparison was assessed using 1-way analysis of variance and chi-square. Univariate and multivariate logistic regression analyses were performed to determine prognostic factors. Main end point was mortality.
RESULTS: A total of 62 patients were included (49 women and 13 men), with a mean age of 53.9 years. The most common comorbidities were diabetes (69.3%) and hypertension (40.3%). Escherichia coli was the most common isolated microorganism (62.7%). MM was provided to 24.2%, minimally invasive treatment to 51.6%, open drainage to 19.3%, and emergency nephrectomy to 4.8%. Overall mortality was 14.5% and was similar among different treatment modalities (P=.06). Survivors were younger (P=.004), had lower creatinine (P=.002), and better estimated glomerular filtration rate (P=.007). In univariate analysis, age (P=.009), creatinine (P=.009), and need for nephrectomy (P=.03) were associated with mortality. In multivariate logistic regression analysis, creatinine (odds ratio 1.56, 95% confidence interval 1.03-2.35, P=.03) and nephrectomy (odds ratio 9.7, 95% confidence interval 1.007-93.51, P=.049) remained significant predictors of mortality.
CONCLUSION: EPN needs an aggressive MM and stepwise approach; nephrectomy should be the last resort of treatment. Creatinine level and need for nephrectomy are the strongest predictors of mortality according our analysis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24726310     DOI: 10.1016/j.urology.2014.02.010

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  11 in total

1.  Emphysematous pyelonephritis: Changing trend of clinical spectrum, pathogenesis, management and outcome.

Authors:  Ashok Kumar Sokhal; Manoj Kumar; Bimalesh Purkait; Ankur Jhanwar; Kawaljit Singh; Ankur Bansal; Satyanarayan Sankhwar
Journal:  Turk J Urol       Date:  2017-01-27

2.  Deriving a management algorithm for emphysematous pyelonephritis: Can we rely on minimally invasive strategies or should we be opting for earlier nephrectomy?

Authors:  Eve Boakes; Deepak Batura
Journal:  Int Urol Nephrol       Date:  2017-09-20       Impact factor: 2.370

Review 3.  Prevalence and Risk Factors of Mortality in Emphysematous Pyelonephritis Patients: A Meta-Analysis.

Authors:  Xuan Thai Ngo; Tuan Thanh Nguyen; Ryan W Dobbs; Minh Sam Thai; Duc Huy Vu; Le Quy Van Dinh; Khoa Quy; Hieu Trong Le; Tien-Dat Hoang; Hanh Thi Tuyet Ngo; Trinh Ngoc Khanh Van; Ho Yee Tiong; Huy Gia Vuong
Journal:  World J Surg       Date:  2022-07-08       Impact factor: 3.282

4.  Emphysematous pyelonephritis: Six case reports and review of literature.

Authors:  Li-Ping Ma; Ning Zhou; Yan Fu; Yan Liu; Cong Wang; Bin Zhao
Journal:  World J Clin Cases       Date:  2022-04-06       Impact factor: 1.534

5.  Risk of SOFA Deterioration in Conservative Treatment for Emphysematous Pyelonephritis: Pitfalls of Current Trends in Therapeutics from Multicenter Clinical Experience.

Authors:  Michinobu Ozawa; Osamu Ichiyanagi; Suguru Fujita; Sei Naito; Hiroki Fukuhara; Shinta Suenaga; Satoshi Takai; Takafumi Narisawa; Noriyuki Hosoya; Tatsuya Ishii; Takuya Yamanobe; Akinori Muto; Hitoshi Suzuki; Hayato Nishida; Tomoyuki Kato; Norihiko Tsuchiya
Journal:  Curr Urol       Date:  2019-05-10

Review 6.  A systematic review and meta-analysis of risk factors and treatment choices in emphysematous pyelonephritis.

Authors:  Rajeev Desai; Deepak Batura
Journal:  Int Urol Nephrol       Date:  2022-02-01       Impact factor: 2.370

7.  Emphysematous pyelonephritis: Does a standard management algorithm and a prognostic scoring model optimize patient outcomes?

Authors:  Amit Jain; Ramanitharan Manikandan; Lalgudi Narayanan Dorairajan; Sreerag Kodakkattil Sreenivasan; Sriharsha Bokka
Journal:  Urol Ann       Date:  2019 Oct-Dec

8.  Recommended Initial Antimicrobial Therapy for Emphysematous Pyelonephritis: 51 Cases and 14-Year-Experience of a Tertiary Referral Center.

Authors:  Yu-Chuan Lu; Jian-Hua Hong; Bing-Juin Chiang; Yuan-Hung Pong; Po-Ren Hsueh; Chao-Yuan Huang; Yeong-Shiau Pu
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

9.  Clinical Practice Guidelines for the Antibiotic Treatment of Community-Acquired Urinary Tract Infections.

Authors:  Cheol In Kang; Jieun Kim; Dae Won Park; Baek Nam Kim; U Syn Ha; Seung Ju Lee; Jeong Kyun Yeo; Seung Ki Min; Heeyoung Lee; Seong Heon Wie
Journal:  Infect Chemother       Date:  2018-03

10.  Bilateral emphysematous pyelonephritis cured by antibiotics alone in a black African woman.

Authors:  G Asafu Adjaye Frimpong; E Aboagye; P Amankwah; J Boateng; A S B Amoako-Adu
Journal:  Radiol Case Rep       Date:  2018-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.